FFTY:NYE-Innovator IBD® 50 ETF (USD)

ETF | Mid-Cap Growth |

Last Closing

USD 26.8007

Change

-0.18 (-0.66)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-04 )

Largest Industry Peers for Mid-Cap Growth

Symbol Name Price(Change) Market Cap
IWP iShares Russell Mid-Cap Growth..

+0.10 (+0.08%)

USD 15.96B
VOT Vanguard Mid-Cap Growth Index ..

-0.17 (-0.07%)

USD 14.56B
IJK iShares S&P Mid-Cap 400 Growth..

+0.37 (+0.41%)

USD 9.29B
XMMO Invesco S&P MidCap Momentum ET..

+0.32 (+0.26%)

USD 2.61B
IVOG Vanguard S&P Mid-Cap 400 Growt..

+0.47 (+0.41%)

USD 1.09B
ETHO Amplify ETF Trust

+0.12 (+0.21%)

USD 0.18B
CWS AdvisorShares Focused Equity E..

+0.18 (+0.27%)

USD 0.18B
IPO Renaissance IPO ETF

-0.24 (-0.54%)

USD 0.15B
BFOR Barron's 400 ETF

N/A

USD 0.15B
PEXL Pacer US Export Leaders ETF

N/A

USD 0.06B

ETFs Containing FFTY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Mid-Cap Growth) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.97% 56% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.97% 56% F 62% D
Trailing 12 Months  
Capital Gain 24.77% 61% D- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.77% 61% D- 70% C-
Trailing 5 Years  
Capital Gain -19.59% 39% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.59% 39% F 33% F
Average Annual (5 Year Horizon)  
Capital Gain -1.69% 11% F 26% F
Dividend Return -1.02% 11% F 18% F
Total Return 0.67% 67% D+ 16% F
Risk Return Profile  
Volatility (Standard Deviation) 29.70% 28% F 35% F
Risk Adjusted Return -3.45% 11% F 21% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.